CII
CRSP icon

Capital International Inc’s CRISPR Therapeutics CRSP Stock Holding History

Capital International Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
34,560
+220
+0.6% +$11.6K 0.01% 275
2026
Q1 		$1.63M Buy
34,340
+1,361
+4% +$71.8K 0.01% 275
2025
Q4 		$1.73M Sell
32,979
-725
-2% -$43.4K 0.01% 285
2025
Q3 		$2.18M Buy
33,704
+2,059
+7% +$118K 0.02% 270
2025
Q2 		$1.54M Sell
31,645
-39,802
-56% -$1.54M 0.02% 273
2025
Q1 		$2.43M Sell
71,447
-27,845
-28% -$1.18M 0.03% 254
2024
Q4 		$3.91M Sell
99,292
-3,284
-3% -$155K 0.05% 235
2024
Q3 		$4.82M Buy
102,576
+398
+0.4% +$20.2K 0.06% 209
2024
Q2 		$5.52M Buy
102,178
+10,517
+11% +$608K 0.07% 204
2024
Q1 		$6.25M Buy
91,661
+23,007
+34% +$1.65M 0.08% 195
2023
Q4 		$4.3M Buy
68,654
+341
+0.5% +$18.9K 0.07% 213
2023
Q3 		$3.1M Buy
68,313
+3,063
+5% +$158K 0.06% 209
2023
Q2 		$3.66M Buy
65,250
+4,195
+7% +$238K 0.07% 207
2023
Q1 		$2.76M Buy
61,055
+11,805
+24% +$573K 0.06% 200
2022
Q4 		$2M Sell
49,250
-3,939
-7% -$209K 0.04% 218
2022
Q3 		$3.48M Buy
53,189
+9,564
+22% +$693K 0.08% 185
2022
Q2 		$2.65M Buy
43,625
+7,444
+21% +$438K 0.04% 204
2022
Q1 		$2.27M Sell
36,181
-15,264
-30% -$958K 0.03% 229
2021
Q4 		$3.9M Buy
51,445
+2,287
+5% +$200K 0.04% 217
2021
Q3 		$5.5M Sell
49,158
-4,114
-8% -$517K 0.05% 195
2021
Q2 		$8.62M Sell
53,272
-17,463
-25% -$2.12M 0.08% 174
2021
Q1 		$8.62M Sell
70,735
-47,912
-40% -$7.23M 0.08% 170
2020
Q4 		$18.2M Buy
118,647
+6,867
+6% +$812K 0.17% 129
2020
Q3 		$9.35M Buy
+111,780
New +$9.92M 0.1% 147

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Inc's CRSP Position: Q2 2026 in Review

Capital International Inc increased its CRISPR Therapeutics (CRSP) stake by 0.64% in Q2 2026, buying an estimated $11.6K and bringing the position to 34,560 shares worth $1.88M. The position accounts for 0.01% of the portfolio, ranked #275.

Capital International Inc first reported a position in CRSP in Q3 2020 and has held it in 24 quarters since. The position peaked at $18.2M in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital International Inc held 34,560 shares of CRISPR Therapeutics worth $1.88M as of Q2 2026.
  • Capital International Inc bought 220 CRISPR Therapeutics shares in Q2 2026, an estimated $11.6K.
  • CRISPR Therapeutics made up 0.01% of Capital International Inc's portfolio in Q2 2026, its #275 holding.
  • Capital International Inc first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Capital International Inc's CRISPR Therapeutics position peaked at $18.2M in Q4 2020.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital International Inc's 13F filing for Q2 2026, filed 12 Aug 2026.